Crystal Mallow

459 total citations
16 papers, 227 citations indexed

About

Crystal Mallow is a scholar working on Cellular and Molecular Neuroscience, Oncology and Immunology. According to data from OpenAlex, Crystal Mallow has authored 16 papers receiving a total of 227 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cellular and Molecular Neuroscience, 7 papers in Oncology and 6 papers in Immunology. Recurrent topics in Crystal Mallow's work include Axon Guidance and Neuronal Signaling (11 papers), Phagocytosis and Immune Regulation (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Crystal Mallow is often cited by papers focused on Axon Guidance and Neuronal Signaling (11 papers), Phagocytosis and Immune Regulation (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Crystal Mallow collaborates with scholars based in United States, Germany and United Kingdom. Crystal Mallow's co-authors include Ernest Smith, Maurice Zauderer, Christine Reilly, Sebold Torno, Alan S. Jonason, Holm Bußler, Mark Paris, Elizabeth E. Evans, Terrence L. Fisher and Ekaterina Klimatcheva and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Crystal Mallow

14 papers receiving 221 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Crystal Mallow United States 4 93 80 64 56 22 16 227
Sebold Torno United States 4 86 0.9× 95 1.2× 68 1.1× 48 0.9× 22 1.0× 5 222
Hrishikesh K. Srinagesh United States 4 41 0.4× 26 0.3× 66 1.0× 31 0.6× 11 0.5× 6 213
Sara Lewis United States 7 34 0.4× 61 0.8× 79 1.2× 33 0.6× 18 0.8× 13 227
Nicola Scott United Kingdom 8 162 1.7× 27 0.3× 242 3.8× 48 0.9× 23 1.0× 11 353
César Márquez United States 8 37 0.4× 53 0.7× 134 2.1× 64 1.1× 16 0.7× 11 312
Tom Hartwig Switzerland 5 257 2.8× 34 0.4× 67 1.0× 40 0.7× 49 2.2× 5 393
Johannes C. Melms United States 8 51 0.5× 24 0.3× 102 1.6× 65 1.2× 27 1.2× 15 240
Florence Marsais Belgium 10 106 1.1× 44 0.6× 71 1.1× 38 0.7× 15 0.7× 14 308
Alice Bernard Germany 7 47 0.5× 25 0.3× 77 1.2× 17 0.3× 8 0.4× 18 195

Countries citing papers authored by Crystal Mallow

Since Specialization
Citations

This map shows the geographic impact of Crystal Mallow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Crystal Mallow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Crystal Mallow more than expected).

Fields of papers citing papers by Crystal Mallow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Crystal Mallow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Crystal Mallow. The network helps show where Crystal Mallow may publish in the future.

Co-authorship network of co-authors of Crystal Mallow

This figure shows the co-authorship network connecting the top 25 collaborators of Crystal Mallow. A scholar is included among the top collaborators of Crystal Mallow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Crystal Mallow. Crystal Mallow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Steuer, Conor, Elizabeth E. Evans, Terrence L. Fisher, et al.. (2025). Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer.. Journal of Clinical Oncology. 43(16_suppl). 103–103.
2.
3.
Ruffin, Ayana T., Brian M. Olson, Crystal Mallow, et al.. (2023). 629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26hi T cell in patients with resectable stage III melanoma. SHILAP Revista de lepidopterología. A718–A718. 1 indexed citations
4.
Evans, Elizabeth E., Vikas Mishra, Crystal Mallow, et al.. (2022). Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity. Journal of Neuroinflammation. 19(1). 200–200. 21 indexed citations
5.
Fisher, Terrence L., Elizabeth E. Evans, Crystal Mallow, et al.. (2022). Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84).. Journal of Clinical Oncology. 40(16_suppl). e18033–e18033. 1 indexed citations
6.
7.
8.
Lowe, Michael, Brian M. Olson, Anthony P. Martinez, et al.. (2020). Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.. Journal of Clinical Oncology. 38(15_suppl). 10061–10061. 2 indexed citations
9.
Shafique, Michael, Terrence L. Fisher, Elizabeth E. Evans, et al.. (2020). Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies.. Journal of Clinical Oncology. 38(5_suppl). 75–75. 2 indexed citations
10.
Shafique, Michael, Terrence L. Fisher, Elizabeth E. Evans, et al.. (2020). Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.. Journal of Clinical Oncology. 38(15_suppl). 3011–3011. 1 indexed citations
11.
Ruffolo, Luis I., Nicholas A. Ullman, Katherine M. Jackson, et al.. (2020). Antibody blockade of semaphorin 4D to sensitize pancreatic cancer to immune checkpoint blockade.. Journal of Clinical Oncology. 38(5_suppl). 26–26. 2 indexed citations
12.
Lesinski, Gregory B., Terrence L. Fisher, Elizabeth E. Evans, et al.. (2019). Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors. Cancer Research. 79(13_Supplement). CT016–CT016. 2 indexed citations
13.
Shafique, Michael, Terrence L. Fisher, Elizabeth E. Evans, et al.. (2019). Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.. Journal of Clinical Oncology. 37(15_suppl). 2601–2601. 2 indexed citations
14.
Evans, Elizabeth E., Alan S. Jonason, Holm Bußler, et al.. (2015). Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunology Research. 3(6). 689–701. 88 indexed citations
15.
Klimatcheva, Ekaterina, Christine Reilly, Sebold Torno, et al.. (2015). CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunology. 16(1). 6–6. 94 indexed citations
16.
Evans, Elizabeth E., Siwen Hu‐Lieskovan, Holm Bußler, et al.. (2015). Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations. Journal for ImmunoTherapy of Cancer. 3(S2). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sebold Torno Breakdown of academic impact, for papers by Hrishikesh K. Srinagesh Breakdown of academic impact, for papers by Sara Lewis Breakdown of academic impact, for papers by Nicola Scott Breakdown of academic impact, for papers by César Márquez Breakdown of academic impact, for papers by Tom Hartwig Breakdown of academic impact, for papers by Johannes C. Melms Breakdown of academic impact, for papers by Florence Marsais Breakdown of academic impact, for papers by Alice Bernard
Rankless by CCL
2026